Kisspeptin-10 Shows Promise for Gestational Diabetes by Reducing Insulin Resistance

Gestational Diabetes Mellitus (GDM) is a prevalent and serious complication of pregnancy, characterized by insulin resistance and impaired glucose tolerance that develops or is first recognized during gestation. This condition can lead to adverse outcomes for both the mother and the developing fetus, including increased risk of preeclampsia, macrosomia (large babies), and future development of type 2 diabetes for the mother. A key pathological feature of GDM involves dysfunctional placental trophoblast cells, which are crucial for nutrient transfer and hormone production, often exhibiting heightened insulin resistance. Despite its significant impact, current treatment options primarily focus on diet, exercise, and insulin therapy, highlighting a critical need for novel therapeutic strategies that specifically target the underlying mechanisms. This study sought to investigate the potential of Kisspeptin-10 to alleviate GDM symptoms by addressing insulin resistance in these vital placental cells.